Overall, the evidence suggests that the dysregulation of NKA is a key factor in the pathogenesis of T2D and its complications, highlighting the importance of further research into targeted therapies that could restore NKA function and improve metabolic outcomes in diabetic patients. This evidence concerns the gene TAC1 and type 2 diabetes mellitus.